This study looks at a new treatment called ASP7317 for a condition called geographic atrophy, which is when older adults lose their central vision because of dry age-related macular degeneration (AMD). AMD damages a part of the eye called the macula, making it hard to see clearly. The ASP7317 are special human stem cells that are injected under the macula to help replace damaged cells and possibly improve vision. The study will check if ASP7317 is safe and how well people can handle it, and if it helps improve vision.
The study is open-label, meaning everyone will know they are receiving ASP7317. Participants will be divided into two groups based on the severity of their vision loss, with each group receiving different doses. Participants will take medicine to prevent their bodies from rejecting the new cells and to stop infections. The study will last up to 12 months with several clinic visits required to check for any medical problems and perform eye tests.
- Length of Study: Up to 12 months with several clinic visits.
- Treatment: Involves injections and taking additional medicines.
- Risks: Includes potential side effects from injections and medications.